Pfizer Inc (PFE)

Holds it in the dividend income fund. Has a safe dividend of 6 to 6 1/2% with cash flow. Has a large pipeline of new drugs but it is difficult to predict how many or which ones will take.

Downtrend, lower highs and lower lows. Never assume that the downtrend's over until the chart proves it. Last high and last low are being taken out. If you own, wait till it rallies and then get out.

Worth taking a good, hard look at. Phenomenal yield, and he likes yield. Chart is starting to form a bit of a bottom. Low PE. Has things in the pipeline that the market's not paying for. If you're a longer-term investor, well worth sitting on it and getting rewarded while you wait for an upside pop from the drugs coming through as hoped. 

He's looking at it closely.

Laggard. Doesn't see anything in the healthcare sector that points to a turnaround in the near term. Target on the sector's back on margins. Stock's bounced over the last few weeks, use that to move on.

The problem with pharma is that their drugs all face a patent cliff. Over the last 25 years, pharma companies have tried to sustain themselves through consolidation (mergers, buying small companies). Caution: the dividend may look attractive, but that could be the result of the falling share price.

It needs a catalyst, like a new cancer formulation. Otherwise, you're just collecting that 6.75% dividend.

She likes the space but people are not investing in it. It has a low valuation and is tempting but she prefers elsewhere. It is a global leader in a crowded field. She sees 5% growth so there is some upside.

He owned it but sold. Free cash flow is not abundant and it has a lot of debt. It will take time to turn around but pays a good dividend.

Pays a 7% dividend. Something good must be coming out of their Seagen acquisition. The pipeline looks promising.

Once upon a time, he really liked it. Beaten up for inability to bring forward a weight-loss drug; that may or may not be a realistic critique of this stock long term. Analyst community is really...just...waiting. He sold last year, not ready to come back in. Solid company, an improved oncology pipeline might be a reason to get back in.

It can bottom here. He believes in their Seagen acquisition.

Hangover from its Covid highs. Working on an obesity pill, but pulled back on it. Opportunities in the pipeline. Owned in his income growth portfolio for the yield. Despite the chart, likes it here. Fairly cheap, hopefully hitting a bottom (knock wood).

Failure in a couple of drugs. Huge research program; they will find new drugs. Outstanding stock to accumulate because, at some point, they're going to announce a new drug and the stock will pop. Yield is close to 7-8%.

Thinks dividend is safe, but may be challenged. Spent billions on acquisitions, but hasn't gained much. Not growing. Any boost to bottom line comes from cost cuts. Downhill since Covid, pipeline not strong. Better opportunities in the pharma space, such as MRK. 

You'd have thought they'd be hit more by tariffs, as Trump hammers on that many drug components are made overseas. So the market must be thinking tariffs will benefit pharma, to explain why this name is up on such a tremendously down day. Keeping people guessing and on a knife's edge isn't a bug of the current US administration, it's a feature.

His healthcare investments focus on health management like UNH and medical devices.